PRIVIGEN
CSL BEHRING
Identification
- Active ingredient (INN)
- IMMUNOGLOBULINE HUMAINE NORMALE (IG IV)
- Internal code
- 13 V 451
- Country of Origin
- Switzerland
- Pharmaceutical form
- Injection
- Prescription List
- Highly Regulated (List I)
- Packaging
- flacon/25ml (2.5g)+flacon/50ml (5g) et flacon/100ml (10g)
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Increase blood plasma size in cases of trauma caused by body loss (deficit blood volume), burns, low protein levels (deficit blood proteins) due to surgery or liver failure, adult respiratory distress syndrome, kidney washing, helping to compensate for protein loss and increasing the criminal pressure that results in an expanded volume within the blood vessels.
Associated Conditions
Medically supervised: duration of pregnancy and breastfeeding, where there are insufficient studies on safety of use, the doctor must be consulted before treatment begins; heart, kidney or liver diseases; high blood pressure; pulmonary edema; patients receiving fluids for treatment of dehydration.
Mechanism of Action
A sterile solution, representing a human plasma serum that contains a whole spectrum of serum proteins in a uniform and efficient form, is made from human plasma obtained at least 1,000 donors.
Do you have questions related to this? Ask Sina, artificial intelligence to answer all your medical questions, write your question here, Sina is preparing the answer to you.
Adverse Effects
The following are the main factors that have been identified by the Government: the following.